期刊文献+

2000-2004年我院4种抗癫痫药物血药浓度监测结果分析 被引量:3

An Analysis of the Therapy Drug Monitoring Results of 4 Drugs from 2000 to 2004
暂未订购
导出
摘要 目的:通过对4种抗癫痫药血药浓度有效率和高于及低于有效浓度的百分率的统计分析,有针对性的指导临床,合理调整给药方案。方法:运用回顾性调查方法,对解放军总医院2000年1月-2004年12月所监测的4种抗癫痫药物的血药浓度结果进行分析。结果:4种药物的监测结果中,有效血药浓度范围内结果占年监测例次的百分率以卡马西平为最高,但总体上均较低;而低于有效浓度范围的结果在年监测例次中所占比例较大。结论:血药浓度监测结果是指导临床用药的依据之一,应综合分析患者的用药方案、用药史、实验室数据和临床疗效, 真正做到个体化给药。 Objective: To monitor the blood drug concentrations to adjust the dosage for individual administration. Method : The blood drug concentration results from 2000 to 2004 were analyzed with the retrospective method. Result : The availability proportions of the 4 blood drug concentration results were low, and many points were dropped to the lower range of the effective blood concentration. Conclusion: We should attach importance to the therapy drug monitoring dosage, administration note, and laboratorial examination which are the bases to guide the clinical medication. This way we can adjust the dosage for individual administration.
出处 《药物流行病学杂志》 CAS 2005年第4期223-225,共3页 Chinese Journal of Pharmacoepidemiology
关键词 治疗药物浓度监测 有效浓度范围 抗癫痫药 Therapy drug monitoring Effective blood concentration Antiepileptic
  • 相关文献

参考文献6

二级参考文献13

  • 1张敬军,俞丽云,霍治平,洪震.丙戊酸钠与苯妥英钠或卡马西平相互作用的血浓度观察[J].中国医院药学杂志,1995,15(12):539-540. 被引量:31
  • 2李家泰主编.临床药理学:第二版[M].北京:人民卫生出版社,1998.1223.
  • 3王晓娥 冯义 康雁.抗癫痫药物血药浓度测定的临床意义.中国医院药学杂志,1992,12(9):422-423.
  • 4[3]James EFR. Martindale Pharmacopoeia. 31st edition[M]. London: The Royal Pharmaceutical Society,1996:388.
  • 5[5]Rapeport WG, Mendelo AD, French G, et al. Plasma protein binding and CSF concentration of valproic acid in man following acute oral drug[J]. Br J Clin Pharmac,1983,16:356.
  • 6[3]Amitava D, et al. Carbamazepine salicylate interaction in normal and uremic sera:reduced interaction in uremicsera[J]. Therapeutic Drug Monitoring. 1995, 17:199.
  • 7[4]Antonia P, et al. Interaction between acyclovir and antiepileptic treatment[J]. Therapeutic Drug Monitoring. 1995, 17:312.
  • 8[1]国家食品药品监督管理局.药物非临床研究质量管理规范[S].2003-08-06.
  • 9[5]国家药品监督管理局.新药审批办法[S].2001年1月1日.
  • 10王晓东,王丽.丙戊酸钠对氯硝西泮药物动力学的影响及机理[J].中国医院药学杂志,1998,18(5):197-199. 被引量:8

共引文献101

同被引文献17

  • 1石磊,骆科,姚小莉,楮亚辉,胡丽辉,赵树进.肾移植术后环孢素A的血药浓度监测[J].广东医学,2004,25(9):1057-1058. 被引量:4
  • 2陈刚.治疗药物监测[M].北京:人民军医出版社,1988.405.
  • 3中华人民共和国卫生部药政局.抗菌药物临床应用指导原则[S].1993.
  • 4Karam CM, McKinnon PS, Neuhauser MM, et al. Outcomeassessment of minimizing vancomycin monitoring and dosingadjustments[J]. Pharmacotherapy, 1999, 19(3): 257-266.
  • 5Rybak MJ. The pharmacokinetic and pharmacodynamic propertiesof vancomycin[J]. Clin Infect Dis, 2006, 42(Suppl 1): S35-S39.
  • 6Rybak M, Lomaestro B, Rotschafer JC, et al. Therapeuticmonitoring of vancomycin in adult patients: a consensus reviewof the American Society of Health-System Pharmacists, theInfectious Diseases Society of America, and the Society ofInfectious Diseases Pharmacists[J]. Am J Health Syst Pharm,2009, 66(1): 82-98.
  • 7Lee P, DiPersio D, Jerome RN, et al. Approaching and analyzing a large literature on vancomycin monitoring andpharmacokinetics[J]. J Med Libr Assoc, 2007, 95(4): 374-380.
  • 8Hermsen ED, Hanson M, Sankaranarayanan J, et al. Clinicaloutcomes and nephrotoxicity associated with vancomycin troughconcentrations during treatment of deep-seated infections[J].Expert Opin Drug Saf, 2010, 9(1): 9-14.
  • 9张弨,翟所迪.万古霉素个体化用药的方法学评价[J].药学服务与研究,2008,8(5):381-384. 被引量:1
  • 10刘小丽,黄勋.美国感染病学会、美国药师学会、感染病药师学会共同推荐的万古霉素治疗指南[J].中国感染控制杂志,2009,8(5):373-374. 被引量:29

引证文献3

二级引证文献23

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部